ACC: Analyses Find SGLT2i Therapy Effective But Underutilized
May 19, 2021 Current guidelines strongly recommend use of the therapy for cardiology, diabetes patients In a series of presentations at ACC.21, the virtual meeting of the American College of Cardiology, researchers delivered data to confirm two observations about cardiovascular outcomes in heart failure patients with or without type 2 diabetes (T2D) and/or chronic kidney disease (CDK). First, the use of SGLT2 inhibitors is associated with reduced risk of cardiovascular death, worsening heart failure, and/or hospitalization for heart failure, and second, SGLT2i agents are woefully underused. ...
Source: physiciansweekly.com